Wintermute Reports 400% Surge in OTC Crypto Trading Volumes for 2023

2024-01-10 03:47:52

Last updated: January 10, 2024 06:47 EST . 1 min read

Disclosure: Crypto is a high-risk asset class. This article is provided for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions. We may utilise affiliate links within our content, and receive commission.Source: WintermuteWintermute has reported a staggering 400% increase in over-the-counter (OTC) trading volumes for the year 2023 in the midst of a challenging year for crypto exchanges.In the latest report of its OTC performance, the crypto market maker and liquidity provider Wintermute revealed that its OTC trading volume has surged by four times despite the market downturn.

“From the early resurgence, through a volatile mid-year, ending with a renewed optimism largely fueled by expectations for spot ETF approval,” the report wrote so concluding 2023. “Last year, while the markets took a moment to breathe, we focused on building out our OTC business, increasing our capabilities, and adding new product offerings.”

Wintermute Unveils Transition from Traditional Exchanges to OTC

“On Spot, from H1 to H2 2023, while overall volumes on exchange have declined approximately 13%, during the same period, Wintermute OTC volumes have grown >400%,” wrote the report.

Source: WintermuteIn the first half (H1) of 2023, Wintermute’s OTC volumes initially decreased and remained at a lower level, while the second half (H2) has seen a tremendous boost leading to the total amount quadrupled.

“We saw a significant increase in trading activity with the number of trades growing over 6x, making up over 29 million trades,” wrote the report. “We also saw the largest OTC volume week of >$2 billion during this time.”

Meanwhile, the report has demonstrated a shift from trading at traditional exchanges to OTC volumes. From H1 to H2 2023, the exchange volumes lost 13% as indicated in the report.

“We laid the groundwork for what’s next, particularly with the expansion of our OTC business, which saw impressive grolwth in the second half of the year,” said Wintermute CEO Evgeny Gaevoy.

“A key aspect of this growth has been rei fining our derivatives offering and aligning our suite with the increased dem and we’ve observed for these products,” said Gaevoy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.